Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 346 articles:
HTML format



Single Articles


    May 2020
  1. MANOUCHEHRINIA A, Stridh P, Khademi M, Leppert D, et al
    Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis.
    Neurology. 2020 May 20. pii: WNL.0000000000009571.
    PubMed     Abstract available


  2. LANDMEYER NC, Burkner PC, Wiendl H, Ruck T, et al
    Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Neurology. 2020 May 19. pii: WNL.0000000000009522.
    PubMed     Abstract available


  3. DALE RC, Rostasy K
    Autoimmune pediatric neuropsychiatric symptoms with pain and hypertension: CASPR2 antibody.
    Neurology. 2020 May 18. pii: WNL.0000000000009521.
    PubMed    


  4. SYRBE S, Stettner GM, Bally J, Borggraefe I, et al
    CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension.
    Neurology. 2020 May 18. pii: WNL.0000000000009523.
    PubMed     Abstract available


    April 2020
  5. ARUN T, Pattison L, Palace J
    Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: A retrospective cohort study.
    Neurology. 2020 Apr 30. pii: WNL.0000000000009491.
    PubMed     Abstract available


  6. MATHIS S, Soulages A, Vallat JM, Le Masson G, et al
    History of acute polyradiculoneuropathy (part 1): The prehistory of Guillain-Barre syndrome.
    Neurology. 2020 Apr 28. pii: WNL.0000000000009401.
    PubMed     Abstract available


  7. LANGER-GOULD A, Smith JB, Albers KB, Xiang AH, et al
    Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009374.
    PubMed     Abstract available


  8. DOBSON R, Mowry EM
    Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis.
    Neurology. 2020 Apr 13. pii: WNL.0000000000009369.
    PubMed    


  9. BROWNLEE W, Bourdette D, Broadley S, Killestein J, et al
    Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Neurology. 2020 Apr 2. pii: WNL.0000000000009507.
    PubMed     Abstract available


    March 2020
  10. CARVALHO NETO EG, Gomes MF, Dos Santos IP, Monteiro MD, et al
    Teaching Video NeuroImages: Useful bedside testing for myasthenia gravis: The phenomenon of enhanced ptosis.
    Neurology. 2020 Mar 31. pii: WNL.0000000000009238.
    PubMed    


  11. DE MEEL RHP, Keene KR, Wirth MA, Weber KP, et al
    Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis.
    Neurology. 2020 Mar 26. pii: WNL.0000000000009306.
    PubMed     Abstract available


  12. GRONSETH GS, Barohn R, Narayanaswami P
    Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2020 Mar 25. pii: WNL.0000000000009294.
    PubMed     Abstract available


  13. TINTORE M, Perez-Hoyos S, Otero-Romero S
    Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:456-457.
    PubMed    


  14. JOKUBAITIS VG, Dobson R
    Reader response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455-456.
    PubMed    


  15. GANESH A, Galetta S
    Editors' note: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2020;94:455.
    PubMed    


  16. AMEZCUA L, Smith JB, Gonzales EG, Haraszti S, et al
    Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis.
    Neurology. 2020 Mar 9. pii: WNL.0000000000009210.
    PubMed     Abstract available



  17. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2020 Mar 2. pii: WNL.0000000000008670.
    PubMed    


    February 2020
  18. OBEIDAT AZ, Jassam YN, Hua LH, Cutter G, et al
    Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.
    Neurology. 2020 Feb 27. pii: WNL.0000000000009096.
    PubMed     Abstract available


  19. BRANDSTADTER R, Ayeni O, Krieger SC, Harel NY, et al
    Detection of subtle gait disturbance and future fall risk in early multiple sclerosis.
    Neurology. 2020 Feb 26. pii: WNL.0000000000008938.
    PubMed     Abstract available


  20. FRONTZEK K, Carta M, Losa M, Epskamp M, et al
    Autoantibodies against the prion protein in individuals with PRNP mutations.
    Neurology. 2020 Feb 25. pii: WNL.0000000000009183.
    PubMed     Abstract available


  21. GRAVE C, Boucheron P, Rudant J, Mikaeloff Y, et al
    Seasonal influenza vaccine and Guillain-Barre syndrome: A self-controlled case series study.
    Neurology. 2020 Feb 25. pii: WNL.0000000000009180.
    PubMed     Abstract available


  22. CORTES-VICENTE E, Alvarez-Velasco R, Segovia S, Paradas C, et al
    Clinical and therapeutic features of myasthenia gravis in adults based on age at onset.
    Neurology. 2020 Feb 18. pii: WNL.0000000000008903.
    PubMed     Abstract available


  23. DELCOIGNE B, Manouchehrinia A, Barro C, Benkert P, et al
    Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
    Neurology. 2020 Feb 11. pii: WNL.0000000000009097.
    PubMed     Abstract available


  24. MACARON G, Willis MA, Ontaneda D, Fernandez H, et al
    Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.
    Neurology. 2020;94:273-275.
    PubMed    


  25. KAPOOR M, Spillane J, Englezou C, Sarri-Gonzalez S, et al
    Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy.
    Neurology. 2020;94:e635-e638.
    PubMed     Abstract available


  26. LIPKA AF, Boldingh MI, van Zwet EW, Schreurs MWJ, et al
    Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
    Neurology. 2020;94:e511-e520.
    PubMed     Abstract available


    January 2020
  27. RINGELSTEIN M, Harmel J, Zimmermann H, Brandt AU, et al
    Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
    Neurology. 2020;94:e407-e418.
    PubMed     Abstract available


  28. NEUMANN B, Angstwurm K, Mergenthaler P, Kohler S, et al
    Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases.
    Neurology. 2020;94:e299-e313.
    PubMed     Abstract available


  29. HARTUNG DM, Johnston KA, Geddes J, Bourdette DN, et al
    Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Neurology. 2020 Jan 15. pii: WNL.0000000000008936.
    PubMed     Abstract available


  30. KUNCHOK A, Krecke KN, Flanagan EP, Jitprapaikulsan J, et al
    Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?
    Neurology. 2020;94:85-88.
    PubMed    


  31. HARDING K, Zhu F, Alotaibi M, Duggan T, et al
    Multiple cause of death analysis in multiple sclerosis: A population-based study.
    Neurology. 2020 Jan 13. pii: WNL.0000000000008907.
    PubMed     Abstract available


  32. MARRIE RA, O'Mahony J, Maxwell C, Ling V, et al
    Increased mental health care use by mothers of children with multiple sclerosis.
    Neurology. 2020 Jan 9. pii: WNL.0000000000008871.
    PubMed     Abstract available


    December 2019
  33. ZALOUM A, Falet JR, Elkrief A, Chalk C, et al
    Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Neurology. 2019 Dec 30. pii: WNL.0000000000008860.
    PubMed    


  34. MATTOZZI S, Sabater L, Escudero D, Arino H, et al
    Hashimoto encephalopathy in the 21st century.
    Neurology. 2019 Dec 27. pii: WNL.0000000000008785.
    PubMed     Abstract available


  35. TYLER KL, Ruegg S
    The neuromythology of Hashimoto encephalopathy: The emperor has no clothes.
    Neurology. 2019 Dec 27. pii: WNL.0000000000008776.
    PubMed    


  36. OUDEMAN J, Eftimov F, Strijkers GJ, Schneiders JJ, et al
    Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies.
    Neurology. 2019 Dec 11. pii: WNL.0000000000008697.
    PubMed     Abstract available


  37. ROTSTEIN DL, Marrie RA, Maxwell C, Gandhi S, et al
    MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.
    Neurology. 2019;93:e2203-e2215.
    PubMed     Abstract available


    November 2019
  38. LEE PKJ, Small JE, Vytopil M
    Teaching NeuroImages: Autoimmune glial fibrillary acidic protein meningoencephalomyelitis.
    Neurology. 2019;93:e2076-e2077.
    PubMed    


  39. SAVRANSKY A, Rubstein A, Rios MH, Vergel SL, et al
    Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination.
    Neurology. 2019;93:e2065-e2073.
    PubMed     Abstract available


  40. M HARTUNG D, Alley L, A Johnston K, Bourdette DN, et al
    Qualitative study on the price of drugs for multiple sclerosis: Gaming the system.
    Neurology. 2019 Nov 25. pii: WNL.0000000000008653.
    PubMed     Abstract available


  41. TORABI T, Huttner A, Nowak RJ, Roy B, et al
    Clinical Reasoning: Progressive proximal weakness in a 56-year-old man with bone pain.
    Neurology. 2019;93:939-944.
    PubMed    


  42. MCKAY KA, Ernstsson O, Manouchehrinia A, Olsson T, et al
    Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
    Neurology. 2019 Nov 15. pii: WNL.0000000000008667.
    PubMed     Abstract available


  43. SHAN W, Liu X, Wang Q
    Teaching NeuroImages: (18)F-FDG-PET/SPM analysis in 3 different stages from a patient with LGI-1 autoimmune encephalitis.
    Neurology. 2019;93:e1917-e1918.
    PubMed    


  44. WATERS P, Vincent A
    Myelin oligodendrocyte glycoprotein CSF testing needs testing.
    Neurology. 2019;93:871-872.
    PubMed    


  45. MARIOTTO S, Gajofatto A, Batzu L, Delogu R, et al
    Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Neurology. 2019;93:e1867-e1872.
    PubMed     Abstract available


  46. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Neurology. 2019;93:e1852-e1866.
    PubMed     Abstract available


  47. HUPPERTS R, Smolders J, Vieth R, Holmoy T, et al
    Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a.
    Neurology. 2019;93:e1906-e1916.
    PubMed     Abstract available


  48. BINZER S, McKay KA, Brenner P, Hillert J, et al
    Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2019 Nov 8. pii: WNL.0000000000008617.
    PubMed     Abstract available


    October 2019
  49. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Author response: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:818.
    PubMed    


  50. STEINER I
    Reader response: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:817-818.
    PubMed    


  51. SIEGLER JE 3RD, Galetta S
    Editors' note: Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2019;93:817.
    PubMed    


  52. MURARO PA, Cohen JA
    Complex intensive treatment shows promise against a complex aggressive disease.
    Neurology. 2019;93:776-777.
    PubMed    


  53. YAO MS, Chen S, Liu J
    Mystery Case: Cowden syndrome presenting with paraneoplastic encephalitis.
    Neurology. 2019;93:814-816.
    PubMed    


  54. MATHIS S, Le Masson G, Vallat JM
    Early clinicopathologic description of nodoparanodopathy in the 19th century.
    Neurology. 2019;93:788-792.
    PubMed     Abstract available


  55. BURT RK, Balabanov R, Han X, Burns C, et al
    Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.
    Neurology. 2019;93:e1732-e1741.
    PubMed     Abstract available


  56. VEENHUIZEN Y, Cup EHC, Jonker MA, Voet NBM, et al
    Self-management program improves participation in patients with neuromuscular disease: A randomized controlled trial.
    Neurology. 2019;93:e1720-e1731.
    PubMed     Abstract available


  57. SORMANI MP, Naismith RT
    Measuring disability in multiple sclerosis: Walking plus much more.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008515.
    PubMed    


  58. GOLDMAN MD, LaRocca NG, Rudick RA, Hudson LD, et al
    Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Neurology. 2019 Oct 22. pii: WNL.0000000000008519.
    PubMed     Abstract available



  59. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:769.
    PubMed    


  60. RAE-GRANT AD
    Author response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:765.
    PubMed    


  61. TRAN KR
    Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764-765.
    PubMed    


  62. GANESH A, Galetta S
    Editors' note: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;93:764.
    PubMed    


  63. VAN KEMPEN ZLE, Doesburg D, Dekker I, Lissenberg-Witte BI, et al
    The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    Neurology. 2019;93:e1579-e1586.
    PubMed     Abstract available


  64. DUBEY D, Jitprapaikulsan J, Bi H, Do Campo RV, et al
    Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome.
    Neurology. 2019 Oct 17. pii: WNL.0000000000008472.
    PubMed     Abstract available


  65. PAPP V, Illes Z, Magyari M, Koch-Henriksen N, et al
    Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
    Neurology. 2019;93:723.
    PubMed    


  66. ASGARI N, Flanagan EP
    Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
    Neurology. 2019;93:722-723.
    PubMed    


  67. PINAL-FERNANDEZ I, Mecoli CA, Casal-Dominguez M, Pak K, et al
    More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
    Neurology. 2019 Oct 8. pii: WNL.0000000000008443.
    PubMed     Abstract available


  68. CLIFFORD DB, Tyler KL
    Dosing interval of natalizumab in MS: Do good things come to those who wait?
    Neurology. 2019;93:655-656.
    PubMed    


  69. RYERSON LZ, Foley J, Chang I, Kister I, et al
    Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Neurology. 2019;93:e1452-e1462.
    PubMed     Abstract available


  70. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    PubMed     Abstract available


    September 2019
  71. WATANABE M, Nakamura Y, Michalak Z, Isobe N, et al
    Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Neurology. 2019;93:e1299-e1311.
    PubMed     Abstract available


  72. PFUHL C, Grittner U, Giess RM, Scheel M, et al
    Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2019 Sep 9. pii: WNL.0000000000008237.
    PubMed     Abstract available


  73. EIJLERS AJC, Dekker I, Steenwijk MD, Meijer KA, et al
    Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008198.
    PubMed     Abstract available


  74. BARKHOF F, Kappos L, Wolinsky JS, Li DKB, et al
    Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008189.
    PubMed     Abstract available


  75. CAMMAERT LA, Macleod AD, Mackay GA, Duncan CW, et al
    Reversible tongue atrophy in Lambert-Eaton myasthenic syndrome.
    Neurology. 2019;93:459-460.
    PubMed    


  76. WONG YYM, Bruijstens AL, Barro C, Michalak Z, et al
    Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
    Neurology. 2019;93:e968-e974.
    PubMed     Abstract available


    August 2019

  77. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 29. pii: WNL.0000000000008232.
    PubMed    


  78. FAREZ MF, Correale J, Armstrong MJ, Rae-Grant A, et al
    Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019 Aug 28. pii: WNL.0000000000008157.
    PubMed     Abstract available


  79. YEH EA, Graves J
    Vaccination: Not a trigger for MS.
    Neurology. 2019;93:377-378.
    PubMed    


  80. LAW LY, Riminton DS, Nguyen M, Barnett MH, et al
    The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis.
    Neurology. 2019;93:390-405.
    PubMed     Abstract available


  81. SUMOWSKI JF, Muhlert N
    Dalfampridine improves slowed processing speed in MS: Picking up the pace.
    Neurology. 2019;93:325-326.
    PubMed    


  82. MADIGAN NN, Liewluck T, Milone M, Naddaf E, et al
    Necrotizing autoimmune myopathy with tubular aggregates.
    Neurology. 2019;93:313-314.
    PubMed    


  83. SECHI E, Keegan BM, Kaufmann TJ, Kantarci OH, et al
    Unilateral motor progression in MS: Association with a critical corticospinal tract lesion.
    Neurology. 2019;93:e628-e634.
    PubMed     Abstract available


  84. ZIVADINOV R, Bergsland N, Hagemeier J, Ramasamy DP, et al
    Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.
    Neurology. 2019;93:e611-e623.
    PubMed     Abstract available


  85. SNYDER J, Turner L
    Crowdfunding for stem cell-based interventions to treat neurologic diseases and injuries.
    Neurology. 2019;93:252-258.
    PubMed     Abstract available


  86. HONORAT JA, Lopez-Chiriboga AS, Kryzer TJ, Komorowski L, et al
    Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 1. pii: WNL.0000000000008061.
    PubMed     Abstract available


    July 2019
  87. HAPFELMEIER A, Gasperi C, Donnachie E, Hemmer B, et al
    A large case-control study on vaccination as risk factor for multiple sclerosis.
    Neurology. 2019 Jul 30. pii: WNL.0000000000008012.
    PubMed     Abstract available


  88. SAUCEDO M, Chertcoff A, Bandeo L, Leon Cejas L, et al
    Mystery Case: A 78-year-old man with a gait disorder.
    Neurology. 2019;93:223-227.
    PubMed    


  89. MANDEL-BREHM C, Retallack H, Knudsen GM, Yamana A, et al
    Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis.
    Neurology. 2019;93:e433-e444.
    PubMed     Abstract available


  90. ALGAEED M
    Author response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:184.
    PubMed    


  91. ROBBINS NM, Mozaffar T, Mammen AL, Liewluck T, et al
    Reader response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:183-184.
    PubMed    


  92. GANESH A, Galetta S
    Editors' note: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:182-183.
    PubMed    


  93. MATEEN FJ
    Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world.
    Neurology. 2019;93:176-180.
    PubMed     Abstract available


  94. AL BANNA M, Reeder S, Ghannam M, Robertson J, et al
    Teaching NeuroImages: A case of Vogt-Koyanagi-Harada disease with bilateral retinal detachment.
    Neurology. 2019;93:e421.
    PubMed    


  95. DE GIGLIO L, De Luca F, Gurreri F, Ferrante I, et al
    Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    Neurology. 2019 Jul 22. pii: WNL.0000000000007970.
    PubMed     Abstract available


  96. TITULAER MJ, Irani SR, Lassmann H
    PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?
    Neurology. 2019 Jul 17. pii: WNL.0000000000007965.
    PubMed    


  97. ZEKERIDOU A, Kryzer T, Guo Y, Hassan A, et al
    Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
    Neurology. 2019 Jul 17. pii: WNL.0000000000007971.
    PubMed     Abstract available


  98. SCHMIDT M, Westemeier J, Gross D
    The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist.
    Neurology. 2019;93:109-113.
    PubMed     Abstract available


  99. LAPLAUD DA, Casey R, Barbin L, Debouverie M, et al
    Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007938.
    PubMed     Abstract available


  100. HERSH CM, Marrie RA
    Harnessing real-world data to inform treatment decisions in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007934.
    PubMed    


  101. JONSSON DI, Sveinsson O, Hakim R, Brundin L, et al
    Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.
    Neurology. 2019;93:e181-e189.
    PubMed     Abstract available


  102. CICHOWSKI AJ, Lawson VH
    Patient hand and artistic depiction of chronic inflammatory demyelinating polyradiculoneuropathy.
    Neurology. 2019;93:35-36.
    PubMed    


    June 2019
  103. SECHI E, Shosha E, Williams JP, Pittock SJ, et al
    Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
    Neurology. 2019 Jun 24. pii: WNL.0000000000007828.
    PubMed     Abstract available


  104. DI LUCA DG, Landman J, Ortega MR, Gultekin SH, et al
    Clinical Reasoning: A 47-year-old man with diffuse white matter disease and rapidly progressive dementia.
    Neurology. 2019;92:e2832-e2837.
    PubMed    


  105. VERBOON C, Doets AY, Galassi G, Davidson A, et al
    Current treatment practice of Guillain-Barre syndrome.
    Neurology. 2019 Jun 7. pii: WNL.0000000000007719.
    PubMed     Abstract available


  106. GESSANI A, Cavallieri F, Budriesi C, Zucchi E, et al
    Pearls & Oy-sters: Paroxysmal dysarthria-ataxia syndrome: Acoustic analysis in a case of antiphospholipid syndrome.
    Neurology. 2019;92:e2727-e2731.
    PubMed    


    May 2019
  107. WAUBANT E, Banwell B, Wassmer E, Sormani MP, et al
    Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.
    Neurology. 2019;92:e2538-e2549.
    PubMed     Abstract available


  108. HOWARD JF JR, Bril V, Burns TM, Mantegazza R, et al
    Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007600.
    PubMed     Abstract available


  109. GUIDON AC, Juel VC
    Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007605.
    PubMed    


  110. LANNUZEL A, Ferge JL, Lobjois Q, Signate A, et al
    Long-term outcome in neuroZika: When biological diagnosis matters.
    Neurology. 2019;92:e2406-e2420.
    PubMed     Abstract available


  111. MAMMELE S, Thompson KS, Abe KK
    A rapidly fatal case of anti-NMDA receptor encephalitis due to acute brain edema and herniation.
    Neurology. 2019;92:1014-1016.
    PubMed    


  112. MCKAY KA, Hillert J, Manouchehrinia A
    Long-term disability progression ofpediatric-onset multiple sclerosis.
    Neurology. 2019 May 15. pii: WNL.0000000000007647.
    PubMed     Abstract available


  113. NA S, Lee ES, Kim YD
    Teaching NeuroImages: Pterygoid myositis mimicking giant cell arteritis.
    Neurology. 2019;92:e2297.
    PubMed    


  114. DE BRUIJN MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, et al
    Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis.
    Neurology. 2019;92:e2185-e2196.
    PubMed     Abstract available


  115. PAPADOPOULOU A, Gaetano L, Pfister A, Altermatt A, et al
    Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.
    Neurology. 2019;92:e2240-e2249.
    PubMed     Abstract available


  116. BLANKENBACH K, Schwab N, Hofner B, Adams O, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
    Neurology. 2019;92:e2232-e2239.
    PubMed     Abstract available


  117. CALABRESE M, Gasperini C, Tortorella C, Schiavi G, et al
    "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.
    Neurology. 2019 May 1. pii: WNL.0000000000007573.
    PubMed     Abstract available


  118. BROWNLEE WJ
    Differential diagnosis of multiple sclerosis: The better explanations in clinical practice.
    Neurology. 2019 May 1. pii: WNL.0000000000007566.
    PubMed    


    April 2019
  119. DI LUCA DG, De Leon-Benedetti A, Williamson S, Irving LT, et al
    Teaching Video NeuroImages: A patient with Holmes tremor due to demyelinating lesion of the inferior cerebellar peduncle.
    Neurology. 2019;92:e2179-e2180.
    PubMed    


  120. MAILLART E, Mochel F, Acquaviva C, Maisonobe T, et al
    Severe transient myopathy in a progressive multiple sclerosis patient with high-dose biotin.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007576.
    PubMed    


  121. ZHANG C, Wang SG, Wang Y, Liu XL, et al
    Teaching Video NeuroImages: Cautious walking gait in siblings with hereditary hyperekplexia.
    Neurology. 2019;92:e2068-e2069.
    PubMed    


  122. VILLOSLADA P, Green AJ, Galetta S
    Personalizing medical care for MS patients: Monitoring brainstem damage by infrared oculography.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007493.
    PubMed    


  123. NIJ BIJVANK JA, van Rijn LJ, Balk LJ, Tan HS, et al
    Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007499.
    PubMed     Abstract available


  124. BURON MD, Chalmer TA, Sellebjerg F, Frederiksen J, et al
    Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
    Neurology. 2019;92:e1811-e1820.
    PubMed     Abstract available


  125. BRITTON JW, Dalmau J
    Recognizing autoimmune encephalitis as a cause of seizures: Treating cause and not effect.
    Neurology. 2019 Apr 12. pii: WNL.0000000000007444.
    PubMed    


  126. MEHTA D, Miller C, Arnold DL, Bame E, et al
    Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Neurology. 2019;92:e1724-e1738.
    PubMed     Abstract available


  127. KILLESTEIN J, Reder AT
    Dimethyl fumarate-induced changes in the MS lymphocyte repertoire: No need for subset monitoring.
    Neurology. 2019;92:696-697.
    PubMed    


  128. WAUBANT E, Gilmore W
    Mind the gap: Quantifying gender representation as a first step to solve the problem?
    Neurology. 2019;92:698-699.
    PubMed    


  129. CORTESE M, Chitnis T, Ascherio A, Munger KL, et al
    Total intake of different minerals and the risk of multiple sclerosis.
    Neurology. 2019 Apr 3. pii: WNL.0000000000006800.
    PubMed     Abstract available


  130. MCDONNELL GV, Marriott JJ
    Patient-perceived risks of MS DMTs: Problems of communication and risk management?
    Neurology. 2019;92:647-648.
    PubMed    


  131. JOHANSEN A, Christensen SJ, Scheie D, Hojgaard JLS, et al
    Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
    Neurology. 2019;92:663-674.
    PubMed     Abstract available


  132. MARRIE RA, Garland A, Schaffer SA, Fransoo R, et al
    Traditional risk factors may not explain increased incidence of myocardial infarction in MS.
    Neurology. 2019;92:e1624-e1633.
    PubMed     Abstract available


    March 2019
  133. CONWAY DS
    What is the impact of socioeconomic status on multiple sclerosis?
    Neurology. 2019;92:e1536-e1539.
    PubMed    


  134. GORIS A, Dubois B
    Leveraging human genetics to inform intervention strategies for multiple sclerosis.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007298.
    PubMed    


  135. THOMSON A, Horne R, Chung C, Marta M, et al
    Visibility and representation of women in multiple sclerosis research.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007276.
    PubMed     Abstract available


  136. HARROUD A, Morris JA, Forgetta V, Mitchell R, et al
    Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007325.
    PubMed     Abstract available


  137. KALINCIK T
    Effectiveness of oral multiple sclerosis therapies in clinical context.
    Neurology. 2019 Mar 15. pii: WNL.0000000000007300.
    PubMed    


  138. DE MEO E, Meani A, Moiola L, Ghezzi A, et al
    Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007267.
    PubMed     Abstract available


  139. FOX RJ, Cosenza C, Cripps L, Ford P, et al
    A survey of risk tolerance to multiple sclerosis therapies.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007245.
    PubMed     Abstract available


  140. YEH EA, Eshaghi A
    Evolution of regional brain atrophy in children with multiple sclerosis: Gray matters.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007254.
    PubMed    


  141. BAR-OR A, Grove RA, Tolson JM, Derosier FJ, et al
    Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:543.
    PubMed    


  142. KEARNEY H
    Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542-543.
    PubMed    


  143. LEWIS A, Galetta S
    Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542.
    PubMed    


  144. YEH EA, Nakashima I
    Live-cell based assays are the gold standard for anti-MOG-Ab testing.
    Neurology. 2019;92:501-502.
    PubMed    


  145. NG PS, Dyck PJ, Laughlin RS, Thapa P, et al
    Lumbosacral radiculoplexus neuropathy: Incidence and the association with diabetes mellitus.
    Neurology. 2019;92:e1188-e1194.
    PubMed     Abstract available


  146. WATERS PJ, Komorowski L, Woodhall M, Lederer S, et al
    A multicenter comparison of MOG-IgG cell-based assays.
    Neurology. 2019;92:e1250-e1255.
    PubMed     Abstract available


  147. LAPUCCI C, Saitta L, Bommarito G, Sormani MP, et al
    How much do periventricular lesions assist in distinguishing migraine with aura from CIS?
    Neurology. 2019 Mar 8. pii: WNL.0000000000007266.
    PubMed     Abstract available


  148. CULPEPPER WJ, Marrie RA, Langer-Gould A, Wallin MT, et al
    Validation of an algorithm for identifying MS cases in administrative health claims datasets.
    Neurology. 2019;92:e1016-e1028.
    PubMed     Abstract available


  149. WALLIN MT, Culpepper WJ, Campbell JD, Nelson LM, et al
    The prevalence of MS in the United States: A population-based estimate using health claims data.
    Neurology. 2019;92:e1029-e1040.
    PubMed     Abstract available


  150. KUHLE J, Kropshofer H, Haering DA, Kundu U, et al
    Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Neurology. 2019;92:e1007-e1015.
    PubMed     Abstract available


  151. ZULUAGA MI, Otero-Romero S, Rovira A, Perez-Hoyos S, et al
    Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007178.
    PubMed     Abstract available


  152. CASAL-DOMINGUEZ M, Pinal-Fernandez I, Corse AM, Paik J, et al
    Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007188.
    PubMed     Abstract available


    February 2019
  153. HARDING KE, Wardle M, Carruthers R, Robertson N, et al
    Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007190.
    PubMed     Abstract available


  154. OH J, Ontaneda D, Azevedo C, Klawiter EC, et al
    Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.
    Neurology. 2019 Feb 20. pii: WNL.0000000000007099.
    PubMed     Abstract available


  155. KOCH-HENRIKSEN N
    Author response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  156. SAJEDI SA
    Reader response: Incidence of MS has increased markedly over 6 decades in Denmark particularly with late onset and in women.
    Neurology. 2019;92:397.
    PubMed    


  157. BENARROCH EE
    Autonomic nervous system and neuroimmune interactions: New insights and clinical implications.
    Neurology. 2019;92:377-385.
    PubMed    


  158. DI LUCA DG, Bette S, Singer C, Luca C, et al
    Teaching NeuroImages: Severe spasms resembling status dystonicus as an unusual presentation of stiff-person syndrome.
    Neurology. 2019;92:e748.
    PubMed    


  159. SECHI E, Parks NE, Koeller KK, Flanagan EP, et al
    Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder.
    Neurology. 2019;92:343-344.
    PubMed    


  160. DALLA COSTA G, Martinelli V, Sangalli F, Moiola L, et al
    Prognostic value of serum neurofilaments in patients with clinically isolated syndromes.
    Neurology. 2019;92:e733-e741.
    PubMed     Abstract available


  161. ROCHA EA, Topcuoglu MA, Silva GS, Singhal AB, et al
    RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome.
    Neurology. 2019;92:e639-e647.
    PubMed     Abstract available


  162. BERGER T, Stuve O
    Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007022.
    PubMed    


  163. XU SC, Kardon RH, Leavitt JA, Flanagan EP, et al
    Optical coherence tomography is highly sensitive in detecting prior optic neuritis.
    Neurology. 2019;92:e527-e535.
    PubMed     Abstract available


    January 2019
  164. COHEN J, Sotoca J, Gandhi S, Yeshokumar AK, et al
    Autoimmune encephalitis: A costly condition.
    Neurology. 2019 Jan 23. pii: WNL.0000000000006990.
    PubMed     Abstract available


  165. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  166. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed    


  167. RUEGG S, Yeh EA, Honnorat J
    Forecasting outcomes in anti-NMDAR encephalitis: Clearer prognostic markers needed.
    Neurology. 2019;92:119-120.
    PubMed    


  168. BALU R, McCracken L, Lancaster E, Graus F, et al
    A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.
    Neurology. 2019;92:e244-e252.
    PubMed     Abstract available


  169. ZETTERBERG H, Svenningsson A
    Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006906.
    PubMed    


  170. HONCE JM, Nair KV, Sillau S, Valdez B, et al
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006916.
    PubMed     Abstract available


  171. COHEN BA
    Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006924.
    PubMed    



  172. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:112.
    PubMed    


  173. RAE-GRANT A
    Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:110-111.
    PubMed    


  174. SALTONSTALL L
    Reader response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109-110.
    PubMed    


  175. LEWIS A, Galetta S
    Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109.
    PubMed    


    December 2018
  176. PAPPOLLA A, Midaglia L, Boix Rodriguez CP, Puig AA, et al
    Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006801.
    PubMed    


  177. GASPERINI C, Prosperini L, Tintore M, Sormani MP, et al
    Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006810.
    PubMed     Abstract available


    November 2018
  178. MARRIE RA, Butzkueven H, Ascherio A
    Obesity and brain volume loss in multiple sclerosis.
    Neurology. 2018 Nov 14. pii: WNL.0000000000006638.
    PubMed    


  179. MAHLER C, Unterrainer M, Muth C, Egensperger R, et al
    Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET.
    Neurology. 2018;91:936-937.
    PubMed    


  180. RUCK T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, et al
    Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Neurology. 2018 Nov 7. pii: WNL.0000000000006648.
    PubMed     Abstract available


    October 2018
  181. BROWNLEE WJ
    Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?
    Neurology. 2018 Oct 31. pii: WNL.0000000000006584.
    PubMed    


  182. SOLOMON AJ, Naismith RT, Cross AH
    Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.
    Neurology. 2018 Oct 31. pii: WNL.0000000000006583.
    PubMed     Abstract available


  183. PORTACCIO E, Amato MP
    Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:851.
    PubMed    


  184. SOTGIU S, Eusebi A, Begliuomini C, Guerini FR, et al
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:850.
    PubMed    


  185. PROSCHMANN U, Akgun K, Ziemssen T
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849-850.
    PubMed    


  186. LEWIS A, Galetta S
    Editors' note: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849.
    PubMed    


  187. KRYSKO KM, Graves J, Rensel M, Weinstock-Guttman B, et al
    Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Neurology. 2018 Oct 17. pii: WNL.0000000000006471.
    PubMed     Abstract available


  188. BASAL E, Zalewski N, Kryzer TJ, Hinson SR, et al
    Paraneoplastic neuronal intermediate filament autoimmunity.
    Neurology. 2018 Oct 3. pii: WNL.0000000000006435.
    PubMed     Abstract available


  189. ALGAEED M, Mukharesh L, Heinzelmann M, Kaminski HJ, et al
    Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2018;91:e1365-e1367.
    PubMed    


    September 2018
  190. CAVALLA P, Gilmore W
    Pregnancy in multiple sclerosis: Data from an administrative claims database.
    Neurology. 2018 Sep 28. pii: WNL.0000000000006371.
    PubMed    


  191. BAHEERATHAN A, McNamara C, Kalam S, Rane N, et al
    The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Neurology. 2018;91:572-573.
    PubMed    



  192. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018;91:538.
    PubMed    


    August 2018
  193. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed    


  194. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006246.
    PubMed     Abstract available


  195. BROWNLEE WJ, Miszkiel KA, Tur C, Barkhof F, et al
    Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.
    Neurology. 2018 Aug 17. pii: WNL.0000000000006207.
    PubMed     Abstract available


    July 2018
  196. BEDARF JR, Nelles M, Reimann J, Paus S, et al
    Teaching Video NeuroImages: Propriospinal myoclonus as a sequela of Guillain-Barre syndrome.
    Neurology. 2018;91:e297-e299.
    PubMed    


  197. MARQUES-MATOS C, Melo C, Sampaio M, Rodrigues E, et al
    Child Neurology: Treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity.
    Neurology. 2018;91:98-101.
    PubMed    


    June 2018
  198. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
    Neurology. 2018 Jun 27. pii: WNL.0000000000005853.
    PubMed     Abstract available


  199. PRADOS F, Barkhof F
    Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?
    Neurology. 2018 Jun 27. pii: WNL.0000000000005873.
    PubMed    


  200. HAGENS MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, et al
    Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
    Neurology. 2018 Jun 20. pii: WNL.0000000000005825.
    PubMed     Abstract available


  201. VITT JR, Kreple C, Mahmood N, Dickerson E, et al
    Autoimmune pancerebellitis associated with pembrolizumab therapy.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005781.
    PubMed    


  202. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Abstract available


    May 2018
  203. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Abstract available


  204. KIM DD, Ho C, King R, Morrow SA, et al
    Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.
    Neurology. 2018;90:e1929-e1932.
    PubMed    


  205. LIEWLUCK T
    Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed    


  206. BUDHRAM A
    Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed    


  207. KARAM C, Galetta S
    Editors' note: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:989.
    PubMed    


  208. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Abstract available


  209. SHANKLIN A, Cox A, Ahmed HMA, Lieberman A, et al
    Clinical Reasoning: A 77-year-old man presenting with episodic expressive aphasia.
    Neurology. 2018;90:e1822-e1826.
    PubMed    


  210. DE LORENZO R, Pinal-Fernandez I, Huang W, Albayda J, et al
    Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    Neurology. 2018 May 4. pii: WNL.0000000000005638.
    PubMed     Abstract available


  211. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed    


  212. LOPEZ CHIRIBOGA AS, Matsumoto J, Sorenson E, Klein CJ, et al
    Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity.
    Neurology. 2018;90:e1636-e1637.
    PubMed    


    April 2018
  213. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Abstract available


  214. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Abstract available


  215. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Abstract available


  216. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Abstract available


  217. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Abstract available


  218. HEWETT K, Sanders DB, Grove RA, Broderick CL, et al
    Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
    Neurology. 2018;90:e1425-e1434.
    PubMed     Abstract available


  219. PEDROSO JL, Dutra LA, Espay AJ, Hoftberger R, et al
    Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
    Neurology. 2018;90:746-747.
    PubMed    


  220. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed    


    March 2018
  221. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed    


  222. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed    


  223. FRATTINI E, Monfrini E, Bitetto G, Ferrari B, et al
    Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss.
    Neurology. 2018;90:572-575.
    PubMed    


  224. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Abstract available


  225. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Abstract available


  226. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed    


  227. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Abstract available


  228. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed    


  229. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Abstract available


    February 2018
  230. PATIL A, Shree R, Naheed D, Goyal MK, et al
    Pearls & Oy-sters: Paraneoplastic cerebral vasculitis: Rare cause of spontaneous convexity subarachnoid hemorrhage.
    Neurology. 2018;90:e815-e817.
    PubMed    


  231. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Abstract available


  232. BATEMAN EM, Schleicher WE, Smith EJ, Sweet DR, et al
    Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.
    Neurology. 2018;90:e724-e726.
    PubMed     Abstract available


  233. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Abstract available


  234. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Abstract available


  235. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Abstract available


  236. SALVARANI C, Brown RD Jr, Christianson TJH, Huston J 3rd, et al
    Primary central nervous system vasculitis associated with lymphoma.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005062.
    PubMed     Abstract available


    January 2018
  237. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed    


  238. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Abstract available


  239. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Abstract available


  240. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Abstract available


  241. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Abstract available


  242. ALLENBACH Y, Arouche-Delaperche L, Preusse C, Radbruch H, et al
    Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement.
    Neurology. 2018 Jan 12. pii: WNL.0000000000004923.
    PubMed     Abstract available


  243. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Abstract available


    December 2017
  244. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Abstract available


  245. DUBEY D, Lennon VA, Gadoth A, Pittock SJ, et al
    Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
    Neurology. 2017 Dec 8. pii: WNL.0000000000004803.
    PubMed     Abstract available


  246. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed    


  247. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Abstract available


  248. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed    


    November 2017
  249. BURNOR E, Yang L, Zhou H, Patterson KR, et al
    Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
    Neurology. 2017 Nov 29. pii: WNL.0000000000004773.
    PubMed     Abstract available


  250. KLAWITER EC, Bove R, Elsone L, Alvarez E, et al
    High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
    Neurology. 2017;89:2238-2244.
    PubMed     Abstract available


  251. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Abstract available


  252. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed    


  253. DHAWAN PS, Dyck PJB, Tracy JA, Naddaf E, et al
    Systemic vasculitis with dermatomyositis, hearing loss, neuropathy, and multiorgan dysfunction.
    Neurology. 2017;89:2119-2120.
    PubMed    


  254. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Abstract available


  255. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Abstract available


  256. HOUZEN H, Kondo K, Niino M, Horiuchi K, et al
    Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    Neurology. 2017;89:1995-2001.
    PubMed     Abstract available


  257. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Abstract available


  258. BARNETT C, Bril V, Kapral M, Kulkarni AV, et al
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004676.
    PubMed     Abstract available


    October 2017
  259. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Abstract available


  260. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed    


  261. MATHIS S, Magy L, Le Masson G, Vallat JM, et al
    Did Jules Dejerine describe AMAN at the end of the 19th century?
    Neurology. 2017;89:1749-1753.
    PubMed     Abstract available


  262. KARGIOTIS O, Safouris A, Petrou VN, Magoufis G, et al
    Teaching NeuroImages: Giant cell arteritis presenting with acute ischemic strokes due to diffuse intracranial stenoses.
    Neurology. 2017;89:e190-e191.
    PubMed    


  263. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed    


  264. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Abstract available


    September 2017
  265. LIEWLUCK T
    Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004610.
    PubMed    


  266. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed    


  267. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed    


  268. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed    


  269. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed    


  270. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Abstract available


  271. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Abstract available


  272. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed    


  273. LOPEZ-CHIRIBOGA AS, Clardy SL
    Emerging Subspecialties in Neurology: Autoimmune neurology.
    Neurology. 2017;89:e129-e133.
    PubMed    


  274. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed    


  275. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed    


  276. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Abstract available


  277. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Abstract available


  278. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Abstract available


    August 2017
  279. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Abstract available


  280. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Abstract available


  281. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Abstract available


  282. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed    


  283. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Abstract available


  284. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed    


  285. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Abstract available


  286. SUZUKI S, Ishikawa N, Konoeda F, Seki N, et al
    Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004359.
    PubMed     Abstract available


  287. BEECHER G, Anderson D, Siddiqi ZA
    Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004365.
    PubMed     Abstract available



  288. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed    


  289. HEHIR MK, Hobson-Webb LD, Benatar M, Barnett C, et al
    Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Neurology. 2017 Aug 11. pii: 10.1212/WNL.0000000000004341.
    PubMed     Abstract available


    July 2017
  290. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed    


  291. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed    


  292. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed    


  293. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Abstract available


  294. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Abstract available


  295. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Abstract available



  296. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed    


  297. URUHA A, Suzuki S, Nishino I
    Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2017;89:215.
    PubMed    


  298. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Abstract available


    June 2017
  299. LEWIS EJH, Perkins BA, Lovblom LE, Bazinet RP, et al
    Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
    Neurology. 2017;88:2294-2301.
    PubMed     Abstract available


  300. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Abstract available


  301. BRENNA G, Antozzi C, Montomoli C, Baggi F, et al
    A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004082.
    PubMed     Abstract available


    May 2017
  302. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Abstract available


  303. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed    


  304. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed    


  305. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  306. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed    


  307. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed    


  308. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed    


  309. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Abstract available


  310. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Abstract available


  311. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Abstract available


    April 2017
  312. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Abstract available


  313. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Abstract available


  314. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Abstract available


  315. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Abstract available


    March 2017
  316. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Abstract available


  317. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Abstract available


    February 2017
  318. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Abstract available


  319. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Abstract available


  320. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed    


  321. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed    


  322. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed    


  323. WYNN DP, Donigan JM, Tkach A
    Clinical Reasoning: A 74-year-old woman with bilateral foot pain and a palmar rash.
    Neurology. 2017;88:e44-e50.
    PubMed    


  324. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed    


  325. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed    


    January 2017
  326. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Abstract available


  327. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Abstract available


    December 2016
  328. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Abstract available


  329. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Abstract available


    November 2016
  330. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed    


  331. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed    


    October 2016
  332. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed    


    September 2016
  333. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed    


  334. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed    


  335. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Abstract available


    July 2016
  336. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed    


  337. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Abstract available


  338. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed    


    May 2016
  339. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Abstract available


  340. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Abstract available


  341. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Abstract available


  342. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed    


  343. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Abstract available


  344. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Abstract available


    April 2016
  345. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Abstract available


    March 2016
  346. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: